[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480767":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":19,"responsibleParty":39,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":22,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"First Affiliated Hospital of Guangxi Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Edaravone","EXPERIMENTAL",null,[13],"Drug: Edaravone",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Edaravone injection 30mg three times a day",[9],[20],{"facility":21,"status":22,"city":23,"state":11,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Yi Du","RECRUITING","Nanning","530021","China","CN",{"type":28,"coordinates":29},"Point",[30,31],108.31667,22.81667,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Yi Du, MD","CONTACT","+86 771 5356507","duyinapoleon@gmail.com",{"type":40,"investigatorFullName":21,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Dr.","100480767","edaravone-in-the-treatment-of-optic-neuritis-100480767",false,"NCT05540262","Edaravone in the Treatment of Optic Neuritis","Inclusion Criteria:\n\n1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis\n2. Patients with a first episode of optic neuritis in either eye\n3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone\n\nExclusion Criteria:\n\n1. Myopia over 6 diopters\n2. Refractive media opacity affecting assessment of retinal layers and\u002For visual acuity","ALL","18 Years","70 Years",{"count":52,"type":53},50,"ESTIMATED","INTERVENTIONAL",[56],"NA","Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.",[59],"Optic Neuritis","2025-02-25",{"date":62,"type":63},"2025-02-27","ACTUAL",{"date":65,"type":63},"2022-01-15",{"date":67,"type":53},"2025-12-31",{"name":5,"class":6},1]